GlobalData anticipates notable growth in the head and neck squamous cell carcinoma (HNSCC) therapeutics market across the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China), according to its latest report, Head and Neck Squamous Cell Carcinoma: Eight-Market Drug Forecast and Market Analysis 2024–34 (GDHCHT669). The market is projected to grow from $2.0bn in 2024 to $4.5bn in 2034, at a compound annual growth rate (CAGR) of 8.4%.
This anticipated growth is driven by several factors, including expansion of immune checkpoint inhibitors (ICIs), both through label expansions into earlier treatment settings and the entry of China-origin agents into Western markets. ICIs, including MSD’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab), are already well established as a guideline-preferred therapy for recurrent/metastatic (r/m) HNSCC in each of the 8MM, collectively accounting for 69% of market share or $1.4bn in sales in 2024, with cetuximab the only other meaningful option beyond platinum-based chemotherapy.
Go deeper with GlobalData
In June 2025, the FDA approved pembrolizumab as a single agent for neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin, and then as a single agent for patients with PD-L1-positive resectable locally advanced HNSCC. This marked the first change to the standard of care (SOC) in this setting in over two decades. Adjuvant Opdivo has also demonstrated significant improvements in disease-free survival in the NIVOPOSTOP clinical trials run by the GORTEC group, though regulatory submission has yet to be confirmed. Together with the introduction of subcutaneous formulations, these developments are expected to help Keytruda and Opdivo retain leadership of the space through 2034, despite upcoming losses of patent exclusivity. China-origin ICIs are reshaping the competitive landscape as well, particularly in nasopharyngeal carcinoma, with Junshi Biosciences’ Loqtorzi (toripalimab) and Akeso Biopharma’s penpulimab having both received FDA approval and gained patient share.
A further driver of growth is the 15 pipeline drugs currently in pivotal trials. These upcoming therapies span a broad range of targets and modalities such as antibody-drug conjugates (ADCs), bispecific and bifunctional antibodies, and cancer vaccines, and are designed to build on the established SOC rather than displace it.
Several programs are competing to become the preferred add-on to Keytruda in the first-line (1L) setting, most notably Merus’s petosemtamab, Bicara’s ficerafusp alfa, and PDS Biotech’s PDS0101, each of which has demonstrated encouraging clinical signals, including improved response rates and overall survival outcomes. GlobalData expects the treatment paradigm to shift away from single-agent EGFR or programmed cell death protein 1 (PD‑1) therapies with or without chemotherapy, towards a more diversified set of combination regimens designed to increase response rates and address tumour-specific escape mechanisms. Significant clinical unmet needs persist in the HNSCC landscape, according to key opinion leaders (KOLs) and high-prescribing clinicians interviewed by GlobalData. In r/m disease, median overall survival is approximately 13 months, as only a minority of patients achieve meaningful responses with first-line SOC, underscoring the need for more efficacious treatments. A further gap exists between current SOC protocols, which rely on intensive surgery, prolonged radiation, and full-dose platinum-based chemotherapy, and the clinical reality of frail or elderly patients with comorbidities who frequently cannot tolerate these regimens. Even in patients who can tolerate treatment, surgery and chemoradiation can cause permanent impairment of speech and swallowing, with lasting consequences for quality of life. Taken together, there is a clear need for more effective, less toxic options, yet these gaps are unlikely to be fully addressed by the existing late-stage pipeline.
